HUP0003931A2 - Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents
Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0003931A2 HUP0003931A2 HU0003931A HUP0003931A HUP0003931A2 HU P0003931 A2 HUP0003931 A2 HU P0003931A2 HU 0003931 A HU0003931 A HU 0003931A HU P0003931 A HUP0003931 A HU P0003931A HU P0003931 A2 HUP0003931 A2 HU P0003931A2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- vitronectin receptor
- pharmaceutical compositions
- compositions containing
- receptor antagonist
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 102100022337 Integrin alpha-V Human genes 0.000 title abstract 3
- 108010048673 Vitronectin Receptors Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 2
- 230000024279 bone resorption Effects 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 210000002997 osteoclast Anatomy 0.000 abstract 1
- 230000001599 osteoclastic effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A találmány (I) képletű vegyületre, azaz (S)-4-(karboxi-metil)-8-{3-[(2-piridil)-amino]-1-propoxi}-3-oxo-2-(2,3,4-trifluor-benzil)-2,3,4,5-tetrahidro-lH-2-benzazepinre és gyógyászatilag elfogadhatósóira vonatkozik. A találmány szerinti vegyület gátolja avitronektinnek és más RGD-tartalmú peptideknek a vitronektinreceptorhoz történő kötődését. Az osteoclastokon lévő vitronektinreceptor inhibíciója gátolja az osteoclasticus csontreszorpciót és ígyfelhasználható az olyan betegségek kezelésére, amelyekben acsontreszorpció egy patológiás állapottal, például osteoporosisszalvagy osteoarthritisszel áll összefüggésben. A találmány kiterjed avegyületek új intermediereire, valamint a vegyületeket tartalmazógyógyszerkészítményekre és a vegyületek gyógyászati alkalmazására is. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5986797P | 1997-09-24 | 1997-09-24 | |
| PCT/US1998/019987 WO1999015178A1 (en) | 1997-09-24 | 1998-09-24 | Vitronectin receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0003931A2 true HUP0003931A2 (hu) | 2001-10-28 |
Family
ID=22025805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0003931A HUP0003931A2 (hu) | 1997-09-24 | 1998-09-24 | Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1023073A1 (hu) |
| JP (1) | JP2002500162A (hu) |
| KR (1) | KR20010024249A (hu) |
| CN (1) | CN1271284A (hu) |
| AU (1) | AU9578798A (hu) |
| BR (1) | BR9813214A (hu) |
| CA (1) | CA2304000A1 (hu) |
| HU (1) | HUP0003931A2 (hu) |
| IL (1) | IL135188A0 (hu) |
| NO (1) | NO20001515D0 (hu) |
| PL (1) | PL339414A1 (hu) |
| TR (1) | TR200000786T2 (hu) |
| WO (1) | WO1999015178A1 (hu) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1150965A4 (en) | 1999-02-03 | 2002-05-15 | Merck & Co Inc | BENZAZEPINE DERIVATIVES FOR USE AS ANTAGONISTS OF THE INTEGRIN ALPHA-V RECEPTOR |
| US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| RU2316337C2 (ru) | 2001-04-24 | 2008-02-10 | Мерк Патент Гмбх | КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α |
| WO2003059251A2 (en) | 2001-10-22 | 2003-07-24 | The Scripps Research Institute | Antibody targeting compounds |
| JP2006522139A (ja) | 2003-04-04 | 2006-09-28 | スミスクライン・ビーチャム・コーポレイション | ベンズアゼピンの製造方法およびその中間体 |
| ATE420188T1 (de) | 2004-02-02 | 2009-01-15 | Pioneer Hi Bred Int | Ap2-domäne-transkriptionsfaktor odp2 (ovule development protein 2) und verwendungsverfahren |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| EP2338518A1 (en) | 2006-01-18 | 2011-06-29 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
| BRPI0806596A2 (pt) | 2007-01-18 | 2013-07-23 | Merck Patent Ges Mit Berchraenkter Haftung | medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer |
| EP2221308B1 (en) | 2007-11-16 | 2013-07-10 | Ube Industries, Ltd. | Benzazepinone compound |
| WO2009111679A2 (en) * | 2008-03-06 | 2009-09-11 | Smithkline Beecham Corporation | Process |
| EP2395992A2 (en) | 2009-02-10 | 2011-12-21 | The Scripps Research Institute | Chemically programmed vaccination |
| US20120095215A1 (en) | 2009-03-30 | 2012-04-19 | Ube Industries, Ltd. | Medical composition for treatment or prophylaxis of eye diseases |
| MX2011012491A (es) | 2009-05-25 | 2011-12-14 | Merck Patent Gmbh | Administracion continua de cilengitida en tratamientos contra el cancer. |
| EP2529018B1 (en) | 2009-12-30 | 2016-06-22 | Pioneer Hi-Bred International, Inc. | Methods and compositions for the introduction and regulated expression of genes in plants |
| WO2011082310A2 (en) | 2009-12-30 | 2011-07-07 | Pioneer Hi-Bred International, Inc. | Methods and compositions for targeted polynucleotide modification |
| BR112016027778A2 (pt) | 2014-05-30 | 2017-08-15 | Pfizer | Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
-
1998
- 1998-09-24 EP EP98949471A patent/EP1023073A1/en active Pending
- 1998-09-24 KR KR1020007003093A patent/KR20010024249A/ko not_active Application Discontinuation
- 1998-09-24 JP JP2000512547A patent/JP2002500162A/ja not_active Withdrawn
- 1998-09-24 TR TR2000/00786T patent/TR200000786T2/xx unknown
- 1998-09-24 WO PCT/US1998/019987 patent/WO1999015178A1/en not_active Application Discontinuation
- 1998-09-24 IL IL13518898A patent/IL135188A0/xx unknown
- 1998-09-24 HU HU0003931A patent/HUP0003931A2/hu unknown
- 1998-09-24 CN CN98809494A patent/CN1271284A/zh active Pending
- 1998-09-24 AU AU95787/98A patent/AU9578798A/en not_active Abandoned
- 1998-09-24 CA CA002304000A patent/CA2304000A1/en not_active Abandoned
- 1998-09-24 BR BR9813214-8A patent/BR9813214A/pt not_active Application Discontinuation
- 1998-09-24 PL PL98339414A patent/PL339414A1/xx unknown
-
2000
- 2000-03-23 NO NO20001515A patent/NO20001515D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL135188A0 (en) | 2001-05-20 |
| NO20001515L (no) | 2000-03-23 |
| KR20010024249A (ko) | 2001-03-26 |
| PL339414A1 (en) | 2000-12-18 |
| AU9578798A (en) | 1999-04-12 |
| TR200000786T2 (tr) | 2000-08-21 |
| NO20001515D0 (no) | 2000-03-23 |
| CA2304000A1 (en) | 1999-04-01 |
| WO1999015178A1 (en) | 1999-04-01 |
| JP2002500162A (ja) | 2002-01-08 |
| EP1023073A1 (en) | 2000-08-02 |
| CN1271284A (zh) | 2000-10-25 |
| BR9813214A (pt) | 2000-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0003931A2 (hu) | Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0003949A2 (hu) | Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények | |
| CL2003001743A1 (es) | Compuestos derivados de leucinamida, inhibidores de la cisteina proteasa; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la osteoporosis, enfermedad de paget's, peridontal, perdida | |
| LU91145I2 (fr) | FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX). | |
| BR9714358A (pt) | Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos | |
| GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
| BG104544A (en) | Novel acylguanadine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists | |
| PL398536A1 (pl) | Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV | |
| SE9604341D0 (sv) | Hepta-peptide oxytocin analogue | |
| AR004961A1 (es) | Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para el | |
| HUP0001293A1 (hu) | Heterociklusos vegyületek és ezeket tartalmazó gyógyászati készítmények béta-amiloid-peptidek gátlására | |
| NO20045434L (no) | En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom | |
| DE69400435D1 (de) | Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen | |
| AU6999796A (en) | Heterocyclic compounds as bradykinin antagonists | |
| NO20032261L (no) | Medisinske preparater | |
| BR9509975A (pt) | Formulação farmacêutica | |
| HUP0204511A2 (en) | Use of ppar activator or ligand in preparation of pharmaceutical compositions for treatment of bone diseas | |
| MY133512A (en) | Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | |
| HUP0101963A2 (hu) | Interleukin-1béta átalakító enzim szukcinamid inhibitorai | |
| IL124091A (en) | Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it | |
| BR0115424A (pt) | Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto | |
| HUP0104804A2 (hu) | Tetrahidro-naftiridinil-származék, mint vitronektin receptor antagonista, eljárás előállítására és ezt tartalmazó gyógyszerkészítmény | |
| IL145645A0 (en) | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | |
| EP0952159A3 (en) | Use of somatostatin derivatives and/or of phenylhydrazone derivatives as antinflammatory or analgetic agents | |
| HUP0302397A2 (hu) | Új hetrociklikusos vegyületek és az ezeket tartalmazó gyógyászati készítmények |